The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.

@article{Hartung2014TheNT,
  title={The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.},
  author={Hans-Peter Hartung and Bernd C. Kieseier},
  journal={Current opinion in neurology},
  year={2014},
  volume={27 3},
  pages={243-5}
}
DOI:10.1097/WCO.0000000000000101 In the past, immunotherapy for multiple sclerosis (MS) was dominated by a selection of different interferon-b preparations and glatiramer acetate (so called disease-modifying treatments), all providing a similar level of efficacy in terms of reducing relapse rate and slowing disease progression [1]. A few years ago, natalizumab, the first monoclonal antibody used in neurology, was introduced for the treatment of MS, opening a new era of more effective… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Novel therapeutic options for multiple sclerosis.

Expert review of clinical pharmacology • 2014
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…